盟科药业：2025年前三季度净利润约-1.94亿元

Core Viewpoint - Mengke Pharmaceutical (SH 688373) reported a revenue of approximately 104 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of 6.58%. However, the company recorded a net loss attributable to shareholders of approximately 194 million yuan [1][1][1]. Company Summary - Mengke Pharmaceutical's revenue for the first three quarters of 2025 is about 104 million yuan, which is a 6.58% increase compared to the same period last year [1][1][1]. - The net profit attributable to shareholders for the same period is a loss of approximately 194 million yuan [1][1][1]. - As of the report date, Mengke Pharmaceutical has a market capitalization of 5 billion yuan [1][1][1].